Sign inJoin waitlistJoin the waitlist

Gunjan Shah

Associate Attending Physician · New York Presbyterian Hospital

Credentials: · · · · · ·

History

New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Tufts Medical Center
2012–2015
Memorial Sloan Kettering Cancer Center
2011–2012
Internal Medicine
Thomas Jefferson University Hospital
2008–2011
Temple University School of Medicine
2004–2008

Research

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
New England Journal of Medicine · 2020 · 618 citations
GPRC5D-Targeted CAR T Cells for Myeloma
New England Journal of Medicine · 2022 · 370 citations
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
The Lancet Haematology · 2021 · Last of 16 authors · 305 citations

Michael Scordo
140 papers · 1 as a fellow
SG
Sergio Giralt
126 papers
MP
Miguel-Angel Perales
108 papers
PD
Parastoo Dahi
74 papers
HL
Heather Landau
61 papers
SM
Sham Mailankody
58 papers · 2 as a fellow
Lia Palomba
53 papers
AL
Alexander Lesokhin
52 papers
RS
Roni Shouval
48 papers · 34 as a resident
Saad Usmani
48 papers
NK
Neha Korde
47 papers
DC
David Chung
46 papers

Clinical trials

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2024–2027
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2022–2027
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2026
A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2021–2026